Georgios Kapsas

Georgios Kapsas

Auto-generated profile, based on publicly available information

Georgios Kapsas

Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Centre Rotterdam, Rotterdam, Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSarthak Pati
Sarthak Pati
Ujjwal BaidUjjwal Baid
Ujjwal Baid
BEBrandon Edwards
Brandon Edwards
MSMicah Sheller
Micah Sheller
SWShih-Han Wang
Shih-Han Wang
Spyridon BakasSpyridon Bakas
Spyridon Bakas
Although machine learning (ML) has shown promise across disciplines, out-of-sample generalizability is concerning. This is currently addressed by sharing multi-site data, but such centralization is challenging/infeasible to scale due to various limitations. Federated ML (FL) provides an alternative paradigm for accurate and generalizable ML, by only sharing numerical model updates. Here we present the largest FL study to-date, involving data from 71 sites across 6 continents, to generate an automatic tumor boundary detector for the rare disease of glioblastoma, reporting the largest such dataset in the literature (n = 6, 314). We demonstrate a 33% delineation improvement for the surgically targetable tumor, and 23% for the complete tumor extent, over a publicly trained model. We anticipate our study to: 1) enable more healthcare studies informed by large diverse data, ensuring meaningful results for rare diseases and underrepresented populations, 2) facilitate further analyses for glioblastoma by releasing our consensus model, and 3) demonstrate the FL effectiveness at such scale and task-complexity as a paradigm shift for multi-site collaborations, alleviating the need for data-sharing.

5 July 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
SVSebastian R van der Voort
Sebastian R van der Voort
FIFatih Incekara
Fatih Incekara
MWMaarten M J Wijnenga
Maarten M J Wijnenga
GKGeorgios Kapsas
Georgios Kapsas
RGRenske Gahrmann
Renske Gahrmann
SKStefan Klein
Stefan Klein
Background: Accurate characterization of glioma is crucial for clinical decision making. A delineation of the tumor is also desirable in the initial decision stages but is time-consuming. Previously, deep learning methods have been developed that can either non-invasively predict the genetic or histological features of glioma, or that can automatically delineate the tumor, but not both tasks at the same time. Here, we present our method that can predict the molecular subtype and grade, while simultaneously providing a delineation of the tumor. Methods: We developed a single multi-task convolutional neural network that uses the full 3D, structural, preoperative MRI scans to predict the IDH mutation status, the 1p/19q co-deletion status, and the grade of a tumor, while simultaneously segmenting the tumor. We trained our method using a patient cohort containing 1508 glioma patients from 16 institutes. We tested our method on an independent dataset of 240 patients from 13 different institutes. Results: In the independent test set, we achieved an IDH-AUC of 0.90, an 1p/19q co-deletion AUC of 0.85, and a grade AUC of 0.81 (grade II/III/IV). For the tumor delineation, we achieved a mean whole tumor Dice score of 0.84. Conclusions: We developed a method that non-invasively predicts multiple, clinically relevant features of glioma. Evaluation in an independent dataset shows that the method achieves a high performance and that it generalizes well to the broader clinical population. This first-of-its-kind method opens the door to more generalizable, instead of hyper-specialized, AI methods.

13 December 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SVSebastian R. van der Voort
Sebastian R. van der Voort
FIFatih Incekara
Fatih Incekara
MWMaarten M.J. Wijnenga
Maarten M.J. Wijnenga
GKGeorgios Kapsas
Georgios Kapsas
MGMayke Gardeniers
Mayke Gardeniers
MSMarion Smits
Marion Smits
Purpose: Patients with 1p/19q codeleted low-grade glioma (LGG) have longer overall survival and better treatment response than patients with 1p/19q intact tumors. Therefore, it is relevant to know the 1p/19q status. To investigate whether the 1p/19q status can be assessed prior to tumor resection, we developed a machine learning algorithm to predict the 1p/19q status of presumed LGG based on preoperative MRI. Experimental Design: Preoperative brain MR images from 284 patients who had undergone biopsy or resection of presumed LGG were used to train a support vector machine algorithm. The algorithm was trained on the basis of features extracted from post-contrast T1-weighted and T2-weighted MR images and on patients' age and sex. The performance of the algorithm compared with tissue diagnosis was assessed on an external validation dataset of MR images from 129 patients with LGG from The Cancer Imaging Archive (TCIA). Four clinical experts also predicted the 1p/19q status of the TCIA MR images. Results: The algorithm achieved an AUC of 0.72 in the external validation dataset. The algorithm had a higher predictive performance than the average of the neurosurgeons (AUC 0.52) but lower than that of the neuroradiologists (AUC of 0.81). There was a wide variability between clinical experts (AUC 0.45–0.83). Conclusions: Our results suggest that our algorithm can noninvasively predict the 1p/19q status of presumed LGG with a performance that on average outperformed the oncological neurosurgeons. Evaluation on an independent dataset indicates that our algorithm is robust and generalizable.

31 October 2025 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
VMVinod Metta
Vinod Metta
HBHani Taha Sherif Benamer
Hani Taha Sherif Benamer
GKGeorgios Kapsas
Georgios Kapsas
RKRukmini Mridula Kandadai
Rukmini Mridula Kandadai
RARajesh Alugolu
Rajesh Alugolu
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
Magnetic resonance-guided focused ultrasound (MRgFUS) is an emerging and promising technology for treating movement disorders, such as essential tremors and tremor-dominant Parkinson’s disease. MRgFUS utilizes advanced ultrasound transducer emitters to condense sound waves at a precisely defined point. This technology can target various brain areas, such as the pallidothalamic tract, thalamus, and pallidum, to ameliorate some of the symptoms of Parkinson’s disease and other movement disorders, such as dystonic and action-induced tremors. We review the current status of preclinical and clinical trials on the clinical use, treatment outcomes, and indications of MRgFUS.

25 May 2018 in Turkish Journal of Hematology
Verified
Journal Article
Open access
ACAnna Christoforidou
Anna Christoforidou
GKGeorgios Kapsas
Georgios Kapsas
ZBZoe Bezirgiannidou
Zoe Bezirgiannidou
SPSpyros Papamichos
Spyros Papamichos
IKIoannis Kotsianidis
Ioannis Kotsianidis

26 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSarthak Pati
Sarthak Pati
Ujjwal BaidUjjwal Baid
Ujjwal Baid
BEBrandon Edwards
Brandon Edwards
MSMicah Sheller
Micah Sheller
SWShih-Han Wang
Shih-Han Wang
Spyridon BakasSpyridon Bakas
Spyridon Bakas